|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 555 WEST 57TH STREET |
Address2 |
|
City | NEW YORK |
State | NY |
Zip Code | 10019 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16830-12
|
||||||||
|
6. House ID# 324950000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: DAVID RICH |
Date | 7/17/2014 12:05:52 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
ACA (P.L.111-148, P.L.111-52), hospital payment issues, including disproportionate share hospital (DSH); Resident Physician Shortage Reduction Act (S.577; H.R.1180); NYS MRT Waiver Issues; Medicare observation stay policies and payment; Establishing Beneficiary Equity in the Hospital Readmission Program Act (H.R. 4188); Hospital Readmissions Program Accuracy and Accountability Act (S.2501); Improving Medicare Post-Acute Care Transformation Act (S.2553/H.R.4994); House FY15 Budget Resolution, hospital provisions; Medicare Audit Improvement Act (H.R.1250/S.1012); President's FY15 Budget Proposal, hospital payment reductions; DSH Reduction Relief Act (H.R.1920/S.1555); Health information technology issues; CMS-1599-F, provisions related to Two Midnights and Medicare DSH; Two Midnight Delay Act (H.R.3698); Two Midnight Rule Coordination and Improvement Act (S.2082); CMS-1607-P, provisions related to hospitals including short stay payment policies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kenneth |
Raske |
|
|
|
David |
Rich |
|
|
|
Jonathan |
Cooper |
|
|
|
Lloyd |
Bishop |
|
|
|
Susan |
Waltman |
|
|
|
Karen |
Heller |
|
|
|
Elisabeth |
Wynn |
|
|
|
Timothy |
Johnson |
|
|
|
Bruce |
Vladeck |
|
|
|
Kathleen |
Shure |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
ACA (P.L.111-48, 111-152), issues related to coverage for uninsured and delivery system and reimbursement reforms; organ donation issues; issues related to immigration reform; issues related to hospital price transparency; issues related to veterans' access to health care services (H.R.3230/H.R.4810; issues related to the reauthorization of the Terrorism Risk Insurance Act (TRIA)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kenneth |
Raske |
|
|
|
David |
Rich |
|
|
|
Jonathan |
Cooper |
|
|
|
Karen |
Heller |
|
|
|
Elisabeth |
Wynn |
|
|
|
Timothy |
Johnson |
|
|
|
Kathleen |
Shure |
|
|
|
Bruce |
Vladeck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs); 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance and regulatory risk-based framework (FDA-2011-D-0530 and FDA-2014-N-0339); regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); ongoing pharmaceutical issues pertaining to drug shortages and significant price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); maximum allowable cost price transparency (CMS-4159-P).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kenneth |
Raske |
|
|
|
Lee |
Perlman |
|
|
|
Aisling |
Zaccarelli |
|
|
|
David |
Rich |
|
|
|
Jonathan |
Cooper |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOU
16. Specific lobbying issues
FHA hospital and nursing home mortgage insurance programs -- support
17. House(s) of Congress and Federal agencies Check if None
Housing & Urban Development - Dept of (HUD), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kenneth |
Raske |
|
|
|
David |
Rich |
|
|
|
Susan |
Waltman |
|
|
|
Jonathan |
Cooper |
|
|
|
Elisabeth |
Wynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Deductibility of mobile health as eligible expenses for tax purposes (2012-13 Priority Guidance Plan: Regulations Under Code Section 213); medical device tax (FR Doc. 2012-29628).
17. House(s) of Congress and Federal agencies Check if None
Internal Revenue Service (IRS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kenneth |
Raske |
|
|
|
David |
Rich |
|
|
|
Lee |
Perlman |
|
|
|
Aisling |
Zaccarelli |
|
|
|
Jonathan |
Cooper |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |